SOTIO Enters into Multi-Target Antibody Agreement with Biocytogen to Expand ADC Pipeline

Option and license agreement includes multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platformAgreement will enable SOTIO to significantly broaden its next-generation ADC portfolio, including multi-specific ADCsBiocytogen will receive an upfront payment and potential development milestone payments totaling up to $325.5 millionPrague, Czech Republic and Beijing, China, July 16, 2024 SOTIO Biotech, a clinical-stage biopharmaceutical company owned by PPF Group, and Biocytogen (HKEX: 02315), a global biotech company focused on the discovery of novel antibody therapeutics, today announced a research collaboration and exclusive option and license agreement.The agreement grants SOTIO the option to license multiple fully human bispecific antibodies generated with Biocytogen’s proprietary RenLite® platform, which SOTIO will use to develop next-generation antibody-drug conjugates (ADCs) targeting solid tumors. The agreement also includes an option for SOTIO to leverage Biocytogen’s proprietary ADC platform. Biocytogen will be eligible to receive upfront, development, and commercial milestones and royalties on net sales on a product-by-product basis.“SOTIO’s powerful ADC platform brings together multiple technologies, allowing us to tailor our therapeutics to meet the needs of specific cancer types. Specifically, exploiting bispecific targeting in the context of our ADC approaches to improve precision targeting and overcome tumor heterogeneity is particularly appealing,” said Martin Steegmaier, Ph.D., chief scientific officer of SOTIO. “This agreement with Biocytogen complements our existing collaborations with Synaffix, LigaChem, and NBE-Therapeutics, providing SOTIO with access to fully human antibodies from Biocytogen’s state-of-the-art in vivo discovery platform. With the first targets for a bispecific program already selected, we are well-positioned to expand our ADC pipeline and the therapeutic possibilities for patients with solid tumors.”Under the terms of the agreement, Biocytogen is eligible to receive upfront and potential milestone payments worth up to $325.5 million, plus low single-digit royalties on net sales. SOTIO and Biocytogen will collaborate closely during the research phase of the bispecific programs. SOTIO will be responsible for non-clinical and clinical development, manufacturing, and commercialization of the ADC products.“We are eager to deploy Biocytogen’s cutting-edge tools for antibody discovery to support SOTIO’s exciting ADC development plans,” said Yuelei Shen, Ph.D., president and chief executive officer of Biocytogen. “Our unique RenMice® platforms allow us to discover fully human antibodies with high affinity, low immunogenicity, and favorable developability. We look forward to working with SOTIO to advance novel therapeutics that have the potential to improve cancer treatment.”About SOTIO SOTIO Biotech (SOTIO) is shaping the future of targeted cancer therapies by translating compelling science into patient benefit. The SOTIO pipeline includes three clinical-stage programs: SOT102, a next-generation Claudin-18.2-targeted antibody-drug conjugate; BOXR1030, a metabolically-enhanced CAR-T cell therapy targeting GPC3-expressing tumors; and SOT201, a next-generation PD-1-targeting immunocytokine. SOTIO is a member of the PPF Group. SOTIO is a registered trademark of SOTIO Biotech a.s. in selected countries. For more information, please visit the company’s website at www.sotio.com.About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice®, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.Company contacts: Richard Kapsa                                    Head of Communications                      SOTIO Biotech a.s.                             T: +420 224 174 448                           M: +420 603 280 971                           E: kapsa@sotio.com                             Chaoshe Guo Vice President  (Global Head of Business Development) Biocytogen Pharmaceuticals (Beijing) Co., Ltd. M: +86 10-5696 7680 E: chaoshe.guo@bbctg.com.cn Media contacts: Lisa Raffensperger                               Ten Bridge Communications (SOTIO)     M: +1 (617) 903-8783                          E: lisa@tenbridgecommunications.com   Yanan Liu Biocytogen Pharmaceuticals (Beijing) Co., Ltd. M: +86 10-5696 7680 E: yanan.liu@bbctg.com.cn

Biocytogen Enters into Evaluation and Potential Licensing Agreement with BioCopy for TCR-mimic Antibodies

Beijing, China, May 6, 2024 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotechnology company focused on the discovery of novel antibody-based therapeutics, today announced a TCR-mimic antibody evaluation and potential licensing agreement with BioCopy AG (“BioCopy”), a research-based biotechnology company headquartered in Basel, Switzerland. The agreement grants BioCopy access to fully human TCR-mimic antibodies targeting an intracellular antigen generated by Biocytogen’s proprietary RenTCR-mimicTM mice. BioCopy will conduct an evaluation and retain the option to license these antibodies for the development of novel cancer therapies.“We are glad to provide BioCopy with our TCR-mimic antibodies,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Our in vivo matured TCR-mimic antibodies demonstrated favorable affinity and excellent specificity. Combined with BioCopy’s expertise in TCR-mimic antibody screening and engager development, we are optimistic that our collaboration will generate novel drugs that benefit cancer patients.”BioCopy will use Biocytogen’s TCR-mimic antibodies and test them against promising intracellular tumor associated antigens. Here, BioCopy will use its automated end-to-end platform for the optimization of multispecific biotherapeutics to further develop these TCR-mimic antibodies into next-generation oncological drugs.About Biocytogen’s TCR-mimic Antibody Discovery Platform Biocytogen’s TCR-mimic platform focuses on the discovery of fully human antibodies to intracellular targets that are presented on the cell surface by MHC class I molecules. Leveraging proprietary RenTCR-mimicTM (HLA/RenMab) mice and specialized immunization protocols, Biocytogen’s platform is designed to generate TCR-mimic antibodies that are highly specific for peptide/HLA complexes and not HLA itself. Using high-throughput antibody screening platform, Biocytogen swiftly identifies TCR-mimic antibodies with higher specificity and affinity than endogenous TCRs derived from patients to overcome tumor immune escape. Currently, antibody hits for multiple intracellular targets, including TAAs, cancer-testis antigens, mutated protein antigens, and viral protein antigens, are being evaluated in vivo and in vitro. Fully human antibody sequences obtained from the TCR-mimic platform can empower the development of T cell engagers, bispecific/multispecific antibodies, and CAR-T therapies.About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of December 31, 2023, 103 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 47 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.About BioCopy BioCopy is a multinational company headquartered in Switzerland with a state-of-the-art R&D facility in Germany. The company focuses on biotherapeutic drug discovery and development using their end-to-end automated, AI-powered platform. BioCopy is convinced that cancer can be cured with ingenuity and AI, supported by the extraordinary power of our body’s own immune system. With the company’s unique platform BioCopy is working continuously to develop next generation biotherapeutic drug candidates with unprecedented efficacy and safety, transforming today’s pharmaceutical industries.Website: www.biocopy.comBiocytogen Contacts Antibody assets and platforms: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Beijing, China, March 25, 2024 - Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, and ABL Bio Inc. (“ABL”, KOSDAQ: 298380), a Korean clinical-stage biotechnology company developing novel therapeutics in oncology and CNS diseases, today announced a collaboration to develop new bispecific antibody-drug conjugates (bsADCs). Biocytogen’s RenLite® mice platform can produce fully human antibodies with diverse epitopes and high affinity. This platform is notable for its ability to generate antibodies in a common light chain format, offering a distinctive combination of design flexibility, simplified manufacturing processes, and optimal developability for bsADC development. Based on this platform, both companies will be able to discuss expanding their collaboration for various types of ADC development.Dr. Yuelei Shen, President and CEO of Biocytogen, said, “We are very pleased to collaborate with ABL, a company that possesses advanced platforms for cancer immunotherapy and treatments against CNS diseases. ABL’s consistent success in advancing its pipeline strongly showcases its expertise and capabilities in regulatory, clinical development, and business development activities. BsADC drugs derived from our RenLite® mice platform have shown preferable potency in various tumor models, while also exhibiting good safety profiles. We believe our fully human bsADC platform technology, which features increased tumor selectivity, target synergized internalization, and convenient CMC development, will complement ABL's capabilities effectively. Together, we aim to expedite the development of innovative bsADC therapies.”Sang Hoon Lee, CEO of ABL, said, “We are excited to establish this partnership with Biocytogen for bsADCs. This collaboration is one of the stepping stones for getting down to developing bsADCs. We look forward to a productive collaboration, and firmly believe that this partnership will contribute towards creating a distinctive pipeline, ultimately leading to novel therapies that improve the quality of life for patients.”About Biocytogen Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® (RenMabTM/RenLite®/RenNano®/RenTCR-mimicTM) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR-mimic antibody discovery, and has established a sub-brand, RenBiologicsTM, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. As of June 30, 2023, 50 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and 42 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMiceTM, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco), and Germany (Heidelberg). For more information, please visit http://en.biocytogen.com.cn.About ABL Bio ABL Bio Inc. (KOSDAQ: 298380) is a clinical-stage biotechnology company developing antibody therapeutics for immune-oncology and neurodegenerative diseases. With internal R&D and global partnerships, ABL has developed multiple BsAb platforms, such as ‘Grabody-T,’ ‘Grabody-B’ and built an innovative pipeline of multiple clinical and pre-clinical stage drug candidates. In the oncology area, we have developed Grabody-T, a modular 4-1BB engaging platform that has demonstrated superior efficacy and safety. In the neurodegenerative disorder space, we have developed Grabody-B, which is designed to maximize blood-brain barrier (BBB) penetration. Grabody-B is applicable to various CNS targets across a plethora of neurological disorders, potentially providing a breakthrough to address the high unmet medical needs in neurodegeneration. For more information, please visit www.ablbio.com.Biocytogen Contacts Antibody assets and platforms: BD-Licensing@biocytogen.com Media: pr@bbctg.com.cn